Carl Langren - Lumos Pharma Consultant
| LUMO Stock | USD 4.30 0.02 0.46% |
Insider
Carl Langren is Consultant of Lumos Pharma
| Age | 69 |
| Address | 4200 Marathon Boulevard, Austin, TX, United States, 78756 |
| Phone | 512 215 2630 |
| Web | https://lumos-pharma.com |
Lumos Pharma Management Efficiency
The company has return on total asset (ROA) of (0.6964) % which means that it has lost $0.6964 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7283) %, meaning that it created substantial loss on money invested by shareholders. Lumos Pharma's management efficiency ratios could be used to measure how well Lumos Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 1st of December 2024, Return On Tangible Assets is likely to grow to -0.8. In addition to that, Return On Capital Employed is likely to grow to -1.03. At this time, Lumos Pharma's Other Current Assets are very stable compared to the past year. As of the 1st of December 2024, Net Tangible Assets is likely to grow to about 104.9 M, while Total Assets are likely to drop about 38.6 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| David MD | Erasca Inc | 40 | |
| Nik Chetwyn | Erasca Inc | N/A | |
| Mark Wallet | Century Therapeutics | N/A | |
| Michael MBA | Champions Oncology | N/A | |
| Kenneth Cundy | Anebulo Pharmaceuticals | 65 | |
| Luis Borges | Century Therapeutics | 62 | |
| Andrew MBA | Shattuck Labs | 38 | |
| Robert MBA | Eliem Therapeutics | 56 | |
| MD MBA | Shattuck Labs | 65 | |
| LLM JD | Rezolute | 63 | |
| Robyn Sweinhart | Rezolute | N/A | |
| Susan MS | Eliem Therapeutics | N/A | |
| Casi DeYoung | Shattuck Labs | 53 | |
| Wei MD | Erasca Inc | 54 | |
| MBA MD | Eliem Therapeutics | 63 | |
| Fatima MD | Shattuck Labs | N/A | |
| Conor Richardson | Shattuck Labs | N/A | |
| Steven Ruhl | Forte Biosciences | 67 | |
| Abhinav Shukla | Shattuck Labs | ||
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Michael Diem | Century Therapeutics | 53 | |
Management Performance
| Return On Equity | -1.73 | ||||
| Return On Asset | -0.7 |
Lumos Pharma Leadership Team
Elected by the shareholders, the Lumos Pharma's board of directors comprises two types of representatives: Lumos Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lumos. The board's role is to monitor Lumos Pharma's management team and ensure that shareholders' interests are well served. Lumos Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lumos Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Richard Hawkins, CEO Chairman | ||
| Lori CPA, CFO Officer | ||
| MD BA, Chief Officer | ||
| Lisa Miller, Director Relations | ||
| John McKew, Chief President | ||
| Bradley JD, Chief Counsel | ||
| Carl Langren, Consultant | ||
| BBA CPA, Chief Officer | ||
| MD FAAP, Chief Officer | ||
| Alpa Parikh, Senior Management | ||
| Eddie MBA, Corporate Controller |
Lumos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lumos Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.73 | ||||
| Return On Asset | -0.7 | ||||
| Operating Margin | (10.52) % | ||||
| Current Valuation | 23.84 M | ||||
| Shares Outstanding | 8.65 M | ||||
| Shares Owned By Insiders | 32.69 % | ||||
| Shares Owned By Institutions | 24.27 % | ||||
| Number Of Shares Shorted | 89.51 K | ||||
| Price To Earning | (2.37) X | ||||
| Price To Book | 7.57 X |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lumos Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lumos Pharma. If investors know Lumos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lumos Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.28) | Revenue Per Share 0.27 | Quarterly Revenue Growth 102.714 | Return On Assets (0.70) | Return On Equity (1.73) |
The market value of Lumos Pharma is measured differently than its book value, which is the value of Lumos that is recorded on the company's balance sheet. Investors also form their own opinion of Lumos Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lumos Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lumos Pharma's market value can be influenced by many factors that don't directly affect Lumos Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lumos Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lumos Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lumos Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.